Association between -589C/T Polymorphism in IL-4 Gene and the Risk of COPD: A Meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

 TANGBing , KANGLi ,  CHENMin

Department of Traditional Chinese Medicine, the Third People’s Hospital of Chengdu, Chengdu 610031, China;

Corresponding?author：

CHENMin, Email: 150325684@qq.com

Keywords：

COPD; IL-4; Polymorphism; Meta-analysis; Case-control study

DOI：

10.7507/1672-2531.20160103

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the association between -589C/T polymorphism in IL-4 gene and the risk of chronic obstructive pulmonary disease (COPD). Method PubMed, EMbase, CNKI and WanFang Data databases were electronically searched to identify case-control studies which investigated the association between IL-4 -589C/T polymorphism and the risk of COPD. The search date was up to February 23th, 2016. Two reviewers independently screened the studies, extracted data and assessed the risk of bias of included studies, and then meta-analysis was performed by using RevMan 5.3 software. Results A total of 8 case-control studies involving 1?400 COPD cases and 1?073 controls were included in meta-analysis. The results showed that: the -589C/T polymorphism in IL-4 gene was not associated with the risk of COPD (TT+TC vs. CC: OR=0.84, 95%CI 0.61 to 1.15, P=0.27; TT vs. CC+TC: OR=0.95, 95%CI 0.72 to 1.25, P=0.69; TT vs. CC: OR=1.14, 95%CI 0.74 to 1.76, P=0.55; TC vs. CC: OR=0.83, 95%CI 0.66 to 1.05, P=0.12; T vs. C: OR=0.91, 95%CI 0.72 to 1.14, P=0.40). Conclusion The IL-4 -589C/T polymorphism is not associated with the risk of COPD.

Citation： TANGBing, KANGLi, CHENMin. Association between -589C/T Polymorphism in IL-4 Gene and the Risk of COPD: A Meta-analysis. Chinese Journal of Evidence-Based Medicine, 2016, 16(6): 663-667. doi: 10.7507/1672-2531.20160103 Copy

1.	?Reddel HK. Treatment of overlapping asthma-chronic obstructive pulmonary disease: Can guidelines contribute in an evidence-free zone? J Allergy Clin Immunol, 2015, 136(3): 546-552.
2.	Setoguchi Y, Izumi S, Nakamura H, et al. Survey to determine the efficacy and safety of guideline-based pharmacological therapy for chronic obstructive pulmonary disease patients not previously receiving maintenance treatment. Expert Opin Pharmacother, 2015, 16(15): 2271-2281.
3.	Tsiligianni IG, Alma HJ, de Jong C, et al. Investigating sensitivity, specificity, and area under the curve of the Clinical COPD Questionnaire, COPD Assessment Test, and Modified Medical Research Council scale according to GOLD using St George's Respiratory Questionnaire cutoff 25 (and 20) as reference. Int J Chron Obstruct Pulmon Dis, 2016, 11: 1045-1052.
4.	Vanfleteren LE, Spruit MA, Wouters EF, et al. Management of chronic obstructive pulmonary disease beyond the lungs. Lancet Respir Med, 2016, in press.
5.	Jiang S, Yang ZH, Chen YY, et al. MMP-9 genetic polymorphism may confer susceptibility to COPD. Genet Mol Res, 2016, 15(2). .
6.	Condreay L, Huang L, Harris E, et al. Genetic effects on treatment response of umeclidinium/vilanterol in chronic obstructive pulmonary disease. Respir Med, 2016, 114: 123-126.
7.	May RD, Fung M. Strategies targeting the IL-4/IL-13 axes in disease. Cytokine, 2015, 75(1): 89-116.
8.	Homma S, Sakamoto T, Hegab AE, et al. Association of phosphodiesterase 4D gene polymorphisms with chronic obstructive pulmonary disease: relationship to interleukin 13 gene polymorphism. Int J Mol Med, 2006, 18(5): 933-939.
9.	Hegab AE, Sakamoto T, Saitoh W, et al. Polymorphisms of IL4, IL13, and ADRB2 genes in COPD. Chest, 2004, 126(6): 1832-1839.
10.	van der Pouw Kraan TC, Kucukaycan M, Bakker AM, et al. Chronic obstructive pulmonary disease is associated with the -1055 IL-13 promoter polymorphism. Genes Immun, 2002, 3(7): 436-439.
11.	王偉, 余亞娟, 錢冉, 等. IL-13、IL-4和β2-腎上腺素受體基因多態性與慢性阻塞性肺病易感性關系的研究. 臨床內科雜志, 2011, 28(5): 332-334.
12.	Beghe B, Hall IP, Parker SG, et al. Polymorphisms in IL13 pathway genes in asthma and chronic obstructive pulmonary disease. Allergy, 2010, 65(4): 474-481.
13.	曹霞, 李清泉, 陳國忠, 等. 慢性阻塞性肺病患者IL-4、IL-13以及ADRβ_2基因多態性的檢測. 武漢大學學報(醫學版), 2009, 30(2): 219-223.
14.	Trajkov D, Mirkovska-Stojkovikj J, Petlichkovski A, et al. Association of cytokine gene polymorphisms with chronic obstructive pulmonary disease in Macedonians. Iran J Allergy Asthma Immunol, 2009, 8(1): 31-42.
15.	竇麗陽. IL4、IL13及受體基因多態性與中國西南地區漢族人群慢性阻塞性肺疾病易感相關性的研究. 成都: 四川大學, 2007.
16.	Chen B, Luo MX, Zhou X, et al. Correlation Between Interleukin-1beta-511 C/T Polymorphism and Gastric Cancer in Chinese Populations: A Meta-Analysis. Med Sci Monit, 2016, 22: 1742-1750.
17.	Xia Z, Duan F, Jing C, et al. Quantitative assessment of the association between DNMT3B-579G > T polymorphism and cancer risk. Cancer Biomark, 2015, 15(5): 707-716.
18.	龔青, 李勝, 黃靜宇, 等. 腫瘤壞死因子-α基因-308G/A多態性與子宮內膜異位癥相關性的Meta分析. 中國循證醫學雜志, 2016, 16(1): 41-47.
19.	Xie J, Wu H, Xu Y, et al. Gene susceptibility identification in a longitudinal study confirms new loci in the development of chronic obstructive pulmonary disease and influences lung function decline. Respir Res, 2015, 16: 49.
20.	Zhao Z, Peng F, Zhou Y, et al. Exon sequencing identifies a novel CHRNA3-CHRNA5-CHRNB4 variant that increases the risk for chronic obstructive pulmonary disease. Respirology, 2015, 20(5): 790-798.

1. ?Reddel HK. Treatment of overlapping asthma-chronic obstructive pulmonary disease: Can guidelines contribute in an evidence-free zone? J Allergy Clin Immunol, 2015, 136(3): 546-552.
2. Setoguchi Y, Izumi S, Nakamura H, et al. Survey to determine the efficacy and safety of guideline-based pharmacological therapy for chronic obstructive pulmonary disease patients not previously receiving maintenance treatment. Expert Opin Pharmacother, 2015, 16(15): 2271-2281.
3. Tsiligianni IG, Alma HJ, de Jong C, et al. Investigating sensitivity, specificity, and area under the curve of the Clinical COPD Questionnaire, COPD Assessment Test, and Modified Medical Research Council scale according to GOLD using St George's Respiratory Questionnaire cutoff 25 (and 20) as reference. Int J Chron Obstruct Pulmon Dis, 2016, 11: 1045-1052.
4. Vanfleteren LE, Spruit MA, Wouters EF, et al. Management of chronic obstructive pulmonary disease beyond the lungs. Lancet Respir Med, 2016, in press.
5. Jiang S, Yang ZH, Chen YY, et al. MMP-9 genetic polymorphism may confer susceptibility to COPD. Genet Mol Res, 2016, 15(2). .
6. Condreay L, Huang L, Harris E, et al. Genetic effects on treatment response of umeclidinium/vilanterol in chronic obstructive pulmonary disease. Respir Med, 2016, 114: 123-126.
7. May RD, Fung M. Strategies targeting the IL-4/IL-13 axes in disease. Cytokine, 2015, 75(1): 89-116.
8. Homma S, Sakamoto T, Hegab AE, et al. Association of phosphodiesterase 4D gene polymorphisms with chronic obstructive pulmonary disease: relationship to interleukin 13 gene polymorphism. Int J Mol Med, 2006, 18(5): 933-939.
9. Hegab AE, Sakamoto T, Saitoh W, et al. Polymorphisms of IL4, IL13, and ADRB2 genes in COPD. Chest, 2004, 126(6): 1832-1839.
10. van der Pouw Kraan TC, Kucukaycan M, Bakker AM, et al. Chronic obstructive pulmonary disease is associated with the -1055 IL-13 promoter polymorphism. Genes Immun, 2002, 3(7): 436-439.
11. 王偉, 余亞娟, 錢冉, 等. IL-13、IL-4和β2-腎上腺素受體基因多態性與慢性阻塞性肺病易感性關系的研究. 臨床內科雜志, 2011, 28(5): 332-334.
12. Beghe B, Hall IP, Parker SG, et al. Polymorphisms in IL13 pathway genes in asthma and chronic obstructive pulmonary disease. Allergy, 2010, 65(4): 474-481.
13. 曹霞, 李清泉, 陳國忠, 等. 慢性阻塞性肺病患者IL-4、IL-13以及ADRβ_2基因多態性的檢測. 武漢大學學報(醫學版), 2009, 30(2): 219-223.
14. Trajkov D, Mirkovska-Stojkovikj J, Petlichkovski A, et al. Association of cytokine gene polymorphisms with chronic obstructive pulmonary disease in Macedonians. Iran J Allergy Asthma Immunol, 2009, 8(1): 31-42.
15. 竇麗陽. IL4、IL13及受體基因多態性與中國西南地區漢族人群慢性阻塞性肺疾病易感相關性的研究. 成都: 四川大學, 2007.
16. Chen B, Luo MX, Zhou X, et al. Correlation Between Interleukin-1beta-511 C/T Polymorphism and Gastric Cancer in Chinese Populations: A Meta-Analysis. Med Sci Monit, 2016, 22: 1742-1750.
17. Xia Z, Duan F, Jing C, et al. Quantitative assessment of the association between DNMT3B-579G > T polymorphism and cancer risk. Cancer Biomark, 2015, 15(5): 707-716.
18. 龔青, 李勝, 黃靜宇, 等. 腫瘤壞死因子-α基因-308G/A多態性與子宮內膜異位癥相關性的Meta分析. 中國循證醫學雜志, 2016, 16(1): 41-47.
19. Xie J, Wu H, Xu Y, et al. Gene susceptibility identification in a longitudinal study confirms new loci in the development of chronic obstructive pulmonary disease and influences lung function decline. Respir Res, 2015, 16: 49.
20. Zhao Z, Peng F, Zhou Y, et al. Exon sequencing identifies a novel CHRNA3-CHRNA5-CHRNB4 variant that increases the risk for chronic obstructive pulmonary disease. Respirology, 2015, 20(5): 790-798.

Chinese Journal of Evidence-Based Medicine

Association between -589C/T Polymorphism in IL-4 Gene and the Risk of COPD: A Meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content